Component

Human fecal menaquinone association with glycemia, insulin resistance and inflammation

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Longitudinal fecal menaquinone patterns did not associate significantly with glycemia, insulin resistance or inflammatory markers in the recorded cohort.

    Experimental context and source evidence
    evidence_access
    Primary indexed abstract reviewed; full results, tables and supplements not independently extracted.
    experimental_model
    77 overweight Chinese adults during a diet intervention.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Observational association null; not proof of absence of every vitamin-K effect or absorbed exposure.
    plain_language
    Longitudinal fecal menaquinone patterns did not associate significantly with glycemia, insulin resistance or inflammatory markers in the recorded cohort.
    primary_references
    Fecal menaquinone profiles of overweight adults are associated with gut microbiota composition during a gut microbiota-targeted dietary intervention. | 2015 | DOI 10.3945/ajcn.115.109496 | PMID 26016865 | https://pubmed.ncbi.nlm.nih.gov/26016865/ | https://doi.org/10.3945/ajcn.115.109496
    primary_references
    Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. | 2010 | DOI 10.1038/nature09464 | PMID 20953171 | https://pubmed.ncbi.nlm.nih.gov/20953171/ | https://doi.org/10.1038/nature09464
    source_locator
    Reviewed reference lines 31-31; exact primary location described in quoted passage where extracted.

    Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 31–31

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · 77 overweight Chinese adults during a diet intervention. · Recorded from source · Recorded from source

    **Fecal vitamin K is not absorbed vitamin K.** In 77 overweight Chinese adults, fecal menaquinone patterns associated with microbial composition. A diet intervention decreased fecal MK-4, MK-6 and MK-8, but longitudinal menaquinone patterns did not associate with glycemia, insulin resistance or inflammation. Separately, human UBIAD1 silencing reduced MK-4 biosynthesis in labeled-precursor experiments; UBIAD1 is a host prenyltransferase, not a shikimate-pathway enzyme. Neither result proves that microbial shikimate output determines tissue vitamin-K adequacy. [Fecal menaquinone profiles of overweight adults are associated with gut microbiota composition during a gut microbiota-targeted dietary intervention.](https://pubmed.ncbi.nlm.nih.gov/26016865/) [Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme.](https://pubmed.ncbi.nlm.nih.gov/20953171/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.